119 related articles for article (PubMed ID: 20673491)
1. [Detecting EGFR autoantibodies in serums of NSCLC patients with peptide array].
Li Y; Yue W; Wang Y; Zhang L; Gu M; Xu S
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):727-30. PubMed ID: 20673491
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
[TBL] [Abstract][Full Text] [Related]
3. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
4. Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
Campa MJ; Gottlin EB; Herndon JE; Patz EF
J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538
[TBL] [Abstract][Full Text] [Related]
5. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
6. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
7. Detection of
Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response to epidermal growth factor receptor in lung cancer.
Wang Y; Liu F; OuYang S; Liu M; Zhang X; Wang P; Zhao C; Zhang L; Dai L
Immunol Res; 2021 Feb; 69(1):71-80. PubMed ID: 33495907
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
10. Early detection of NSCLC with scFv selected against IgM autoantibody.
Pedchenko T; Mernaugh R; Parekh D; Li M; Massion PP
PLoS One; 2013; 8(4):e60934. PubMed ID: 23585862
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer.
Khattar NH; Coe-Atkinson SP; Stromberg AJ; Jett JR; Hirschowitz EA
Cancer Biol Ther; 2010 Aug; 10(3):267-72. PubMed ID: 20543565
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
13. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928
[TBL] [Abstract][Full Text] [Related]
14. Biomarker studies abound for early detection of lung cancer.
Brower V
J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
[No Abstract] [Full Text] [Related]
15. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
16. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer.
Shan Q; Lou X; Xiao T; Zhang J; Sun H; Gao Y; Cheng S; Wu L; Xu N; Liu S
Cancer Lett; 2013 Jan; 328(1):160-7. PubMed ID: 22922091
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary Study on the Biological Markers for I-IIb Stage Non-small Cell Lung Cancer Based on a Serum-peptidomics].
Hou Y; Guo H; Guo Y; Zhang Y; Han H
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):20-25. PubMed ID: 30674389
[TBL] [Abstract][Full Text] [Related]
18. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
Ghosh G; Yan X; Lee AG; Kron SJ; Palecek SP
Biosens Bioelectron; 2010 Oct; 26(2):424-31. PubMed ID: 20729058
[TBL] [Abstract][Full Text] [Related]
20. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
